Baird analyst Eric Coldwell said they have long posited that Cardinal Health could well absorb the loss of OptumRx given strong underlying market fundamentals, recent performance, and solid BS/CF generation; and it was confirmed today by reiteration of long-term objectives. Baird believe that valuation remains attractive and theu maintain their Outperform rating and $134 price target on Cardinal Health shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH: